Literature DB >> 19814723

The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor.

F Cogé1, S P Guenin, I Fery, M Migaud, S Devavry, C Slugocki, C Legros, C Ouvry, W Cohen, N Renault, O Nosjean, B Malpaux, P Delagrange, J A Boutin.   

Abstract

BACKGROUND AND
PURPOSE: For many years, it was suspected that sheep expressed only one melatonin receptor (closely resembling MT(1) from other mammal species). Here we report the cloning of another melatonin receptor, MT(2), from sheep. EXPERIMENTAL APPROACH: Using a thermo-resistant reverse transcriptase and polymerase chain reaction primer set homologous to the bovine MT(2) mRNA sequence, we have cloned and characterized MT(2) receptors from sheep retina. KEY
RESULTS: The ovine MT(2) receptor presents 96%, 72% and 67% identity with cattle, human and rat respectively. This MT(2) receptor stably expressed in CHO-K1 cells showed high-affinity 2[(125)I]-iodomelatonin binding (K(D)= 0.04 nM). The rank order of inhibition of 2[(125)I]-iodomelatonin binding by melatonin, 4-phenyl-2-propionamidotetralin and luzindole was similar to that exhibited by MT(2) receptors of other species (melatonin > 4-phenyl-2-propionamidotetralin > luzindole). However, its pharmacological profile was closer to that of rat, rather than human MT(2) receptors. Functionally, the ovine MT(2) receptors were coupled to G(i) proteins leading to inhibition of adenylyl cyclase, as the other melatonin receptors. In sheep brain, MT(2) mRNA was expressed in pars tuberalis, choroid plexus and retina, and moderately in mammillary bodies. Real-time polymerase chain reaction showed that in sheep pars tuberalis, premammillary hypothalamus and mammillary bodies, the temporal pattern of expression of MT(1) and MT(2) mRNA was not parallel in the three tissues. CONCLUSION AND IMPLICATIONS: Co-expression of MT(1) and MT(2) receptors in all analysed sheep brain tissues suggests that MT(2) receptors may participate in melatonin regulation of seasonal anovulatory activity in ewes by modulating MT(1) receptor action.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19814723      PMCID: PMC2782334          DOI: 10.1111/j.1476-5381.2009.00453.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

1.  Tight association of the human Mel(1a)-melatonin receptor and G(i): precoupling and constitutive activity.

Authors:  F Roka; L Brydon; M Waldhoer; A D Strosberg; M Freissmuth; R Jockers; C Nanoff
Journal:  Mol Pharmacol       Date:  1999-11       Impact factor: 4.436

2.  Differential modulation of GABAA receptor function by Mel1a and Mel1b receptors.

Authors:  Q Wan; H Y Man; F Liu; J Braunton; H B Niznik; S F Pang; G M Brown; Y T Wang
Journal:  Nat Neurosci       Date:  1999-05       Impact factor: 24.884

3.  Differential coupling of the extreme C-terminus of G protein alpha subunits to the G protein-coupled melatonin receptors.

Authors:  Janice E Drew; Perry Barrett; Shaun Conway; Philippe Delagrange; Peter J Morgan
Journal:  Biochim Biophys Acta       Date:  2002-10-21

4.  MT1 melatonin receptor mRNA tissular localization by PCR amplification.

Authors:  Vincent-Joseph Poirel; Cathy Cailotto; Dominique Streicher; Paul Pévet; Mireille Masson-Pévet; François Gauer
Journal:  Neuro Endocrinol Lett       Date:  2003 Feb-Apr       Impact factor: 0.765

5.  The roles of valine 208 and histidine 211 in ligand binding and receptor function of the ovine Mel1a beta melatonin receptor.

Authors:  S Conway; S J Canning; P Barrett; B Guardiola-Lemaitre; P Delagrange; P J Morgan
Journal:  Biochem Biophys Res Commun       Date:  1997-10-20       Impact factor: 3.575

Review 6.  Pharmacogenomic and structural analysis of constitutive g protein-coupled receptor activity.

Authors:  Martine J Smit; Henry F Vischer; Remko A Bakker; Aldo Jongejan; Henk Timmerman; Leonardo Pardo; Rob Leurs
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

7.  Structure, characterization, and expression of the gene encoding the mouse Mel1a melatonin receptor.

Authors:  A L Roca; C Godson; D R Weaver; S M Reppert
Journal:  Endocrinology       Date:  1996-08       Impact factor: 4.736

8.  The regional and cellular expression profile of the melatonin receptor MT1 in the central dopaminergic system.

Authors:  Tolga Uz; Ahmet D Arslan; Murat Kurtuncu; Marta Imbesi; Mustafa Akhisaroglu; Yogesh Dwivedi; Ghanshyam N Pandey; Hari Manev
Journal:  Brain Res Mol Brain Res       Date:  2005-05-20

9.  Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone.

Authors:  Ying-Hui Wu; Jiang-Ning Zhou; Rawien Balesar; Unga Unmehopa; Aimin Bao; Ralf Jockers; Joop Van Heerikhuize; Dick F Swaab
Journal:  J Comp Neurol       Date:  2006-12-20       Impact factor: 3.215

Review 10.  Melatonin: characteristics, concerns, and prospects.

Authors:  Josephine Arendt
Journal:  J Biol Rhythms       Date:  2005-08       Impact factor: 3.182

View more
  20 in total

Review 1.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

2.  Melatonin MT₁ and MT₂ receptors display different molecular pharmacologies only in the G-protein coupled state.

Authors:  Céline Legros; Séverine Devavry; Sarah Caignard; Clémence Tessier; Philippe Delagrange; Christine Ouvry; Jean A Boutin; Olivier Nosjean
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 3.  Understanding melatonin receptor pharmacology: latest insights from mouse models, and their relevance to human disease.

Authors:  Gianluca Tosini; Sharon Owino; Jean-Luc Guillaume; Ralf Jockers
Journal:  Bioessays       Date:  2014-06-05       Impact factor: 4.345

4.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

5.  MT1 Receptor Signaling Pathways by Impedance Measurement.

Authors:  Anne Bonnaud; Clémence Dupré; Céline Legros; Jean A Boutin
Journal:  Methods Mol Biol       Date:  2022

6.  Why Are We Still Cloning Melatonin Receptors? A Commentary.

Authors:  Célia Gautier; Isabelle Theret; Giulia Lizzo; Gilles Ferry; Sophie-Pénélope Guénin; Jean A Boutin
Journal:  Methods Mol Biol       Date:  2022

Review 7.  Melatonin and Its Role in Lower Urinary Tract Function: An Article Review.

Authors:  Ali Fathollahi; Firouz Daneshgari; Ann T Hanna-Mitchell
Journal:  Curr Urol       Date:  2015-09-04

8.  Pattern of expression of vascular endothelial growth factor and its receptors in the ovine choroid plexus during long and short photoperiods.

Authors:  Aleksandra Szczepkowska; Barbara Wąsowska; Przemysław D Gilun; Christine Lagaraine; Vincent Robert; Laurence Dufourny; Jean-Claude Thiéry; Janina Skipor
Journal:  Cell Tissue Res       Date:  2012-05-24       Impact factor: 5.249

9.  A novel pathway underlying the inhibitory effects of melatonin on isolated rat urinary bladder contraction.

Authors:  June Hyun Han; In Ho Chang; Soon Chul Myung; Moo Yeol Lee; Won Yong Kim; Seo Yeon Lee; Shin Young Lee; Seung Wook Lee; Kyung Do Kim
Journal:  Korean J Physiol Pharmacol       Date:  2012-02-28       Impact factor: 2.016

10.  New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors.

Authors:  Céline Legros; Ulrich Matthey; Teresa Grelak; Sandrine Pedragona-Moreau; Werner Hassler; Saïd Yous; Emmanuel Thomas; Franck Suzenet; Benoît Folleas; François Lefoulon; Pascal Berthelot; Daniel-Henri Caignard; Gérald Guillaumet; Philippe Delagrange; Jean-Louis Brayer; Olivier Nosjean; Jean A Boutin
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.